At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 13 enrolled
Drug / intervention
Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC)
In Brief
A Phase 4 clinical trial evaluating Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol) and Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II) for Allergic Conjunctivitis. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The purpose of this study was to evaluate ocular responses with different allergen provocation methods.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedJan 2011
Primary CompletionMar 2011
TodayJul 2026
First PostedJan 24, 2011
Enrollment StartDec 1, 2010
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.4 years ago
Interventions
Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)drug
One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)other
One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.